243 related articles for article (PubMed ID: 30806888)
1. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.
Yao J; Tan CHP; Schlossman J; Chakhoyan A; Raymond C; Pope WB; Salamon N; Lai A; Ji M; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2019 May; 142(3):587-595. PubMed ID: 30806888
[TBL] [Abstract][Full Text] [Related]
2. pH-Weighted amine chemical exchange saturation transfer echo planar imaging visualizes infiltrating glioblastoma cells.
Patel KS; Yao J; Cho NS; Sanvito F; Tessema K; Alvarado A; Dudley L; Rodriguez F; Everson R; Cloughesy TF; Salamon N; Liau LM; Kornblum HI; Ellingson BM
Neuro Oncol; 2024 Jan; 26(1):115-126. PubMed ID: 37591790
[TBL] [Abstract][Full Text] [Related]
3. Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3 T.
Harris RJ; Cloughesy TF; Liau LM; Nghiemphu PL; Lai A; Pope WB; Ellingson BM
NMR Biomed; 2016 Nov; 29(11):1563-1576. PubMed ID: 27717216
[TBL] [Abstract][Full Text] [Related]
4. Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T.
Wang YL; Yao J; Chakhoyan A; Raymond C; Salamon N; Liau LM; Nghiemphu PL; Lai A; Pope WB; Nguyen N; Ji M; Cloughesy TF; Ellingson BM
AJNR Am J Neuroradiol; 2019 Jun; 40(6):979-986. PubMed ID: 31097430
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI).
Harris RJ; Yao J; Chakhoyan A; Raymond C; Leu K; Liau LM; Nghiemphu PL; Lai A; Salamon N; Pope WB; Cloughesy TF; Ellingson BM
Magn Reson Med; 2018 Nov; 80(5):1962-1978. PubMed ID: 29626359
[TBL] [Abstract][Full Text] [Related]
6. Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging.
Akbari H; Kazerooni AF; Ware JB; Mamourian E; Anderson H; Guiry S; Sako C; Raymond C; Yao J; Brem S; O'Rourke DM; Desai AS; Bagley SJ; Ellingson BM; Davatzikos C; Nabavizadeh A
Sci Rep; 2021 Jul; 11(1):15011. PubMed ID: 34294864
[TBL] [Abstract][Full Text] [Related]
7. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI.
Harris RJ; Cloughesy TF; Liau LM; Prins RM; Antonios JP; Li D; Yong WH; Pope WB; Lai A; Nghiemphu PL; Ellingson BM
Neuro Oncol; 2015 Nov; 17(11):1514-24. PubMed ID: 26113557
[TBL] [Abstract][Full Text] [Related]
8. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.
Grossmann P; Narayan V; Chang K; Rahman R; Abrey L; Reardon DA; Schwartz LH; Wen PY; Alexander BM; Huang R; Aerts HJWL
Neuro Oncol; 2017 Nov; 19(12):1688-1697. PubMed ID: 28499022
[TBL] [Abstract][Full Text] [Related]
9. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
10. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
11. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
Toh CH; Liau CT; Wei KC; Castillo M
J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
[TBL] [Abstract][Full Text] [Related]
12. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
13. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
Ellingson BM; Kim HJ; Woodworth DC; Pope WB; Cloughesy JN; Harris RJ; Lai A; Nghiemphu PL; Cloughesy TF
Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
[TBL] [Abstract][Full Text] [Related]
14. pH-weighted molecular MRI in human traumatic brain injury (TBI) using amine proton chemical exchange saturation transfer echoplanar imaging (CEST EPI).
Ellingson BM; Yao J; Raymond C; Chakhoyan A; Khatibi K; Salamon N; Villablanca JP; Wanner I; Real CR; Laiwalla A; McArthur DL; Monti MM; Hovda DA; Vespa PM
Neuroimage Clin; 2019; 22():101736. PubMed ID: 30826686
[TBL] [Abstract][Full Text] [Related]
15. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
Strowd R; Ellingson B; Raymond C; Yao J; Wen PY; Ahluwalia M; Piotrowski A; Desai A; Clarke JL; Lieberman FS; Desideri S; Nabors LB; Ye X; Grossman S
J Neurooncol; 2023 Oct; 165(1):101-112. PubMed ID: 37864646
[TBL] [Abstract][Full Text] [Related]
16. Systematic Evaluation of Amide Proton Chemical Exchange Saturation Transfer at 3 T: Effects of Protein Concentration, pH, and Acquisition Parameters.
Schmidt H; Schwenzer NF; Gatidis S; Küstner T; Nikolaou K; Schick F; Martirosian P
Invest Radiol; 2016 Oct; 51(10):635-46. PubMed ID: 27272542
[TBL] [Abstract][Full Text] [Related]
17. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
18. Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.
Hattingen E; Jurcoane A; Daneshvar K; Pilatus U; Mittelbronn M; Steinbach JP; Bähr O
Neuro Oncol; 2013 Oct; 15(10):1395-404. PubMed ID: 23925453
[TBL] [Abstract][Full Text] [Related]
19. Early assessment of recurrent glioblastoma response to bevacizumab treatment by diffusional kurtosis imaging: a preliminary report.
Lee CY; Kalra A; Spampinato MV; Tabesh A; Jensen JH; Helpern JA; de Fatima Falangola M; Van Horn MH; Giglio P
Neuroradiol J; 2019 Oct; 32(5):317-327. PubMed ID: 31282311
[TBL] [Abstract][Full Text] [Related]
20. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
